Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of the Response to Therapy With the Combination of Sunitinib and AMG386 in Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 18 Nov 2010
At a glance
- Drugs Sunitinib; Trebananib
- Indications Renal cancer
- Focus Therapeutic Use
- 18 Nov 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 12 Sep 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 18 Aug 2009 New trial record